Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Overall survival lower with cetuximab in oropharyngeal cancer

Mehanna H et al. ESMO 2018, Abstract LBA9_PR

Key clinical point: Radiation and concomitant cisplatin remains the standard of care for patients with low-risk human papillomavirus–positive oropharyngeal cancer.

Major finding: The 2-year overall survival was 97.5% with cisplatin versus 89.4% with cetuximab (P = .001).

Study details: A randomized trial in 334 patients with low-risk oropharyngeal cancer.

Disclosures: The study was sponsored by the University of Warwick (England), University of Birmingham, University of Oxford (England), and Cancer Research UK. Dr. Mehanna reported honoraria from AstraZeneca, MSD, Sanofi Pasteur, and Merck, and is a director and stockholder of the Warwickshire Head and Neck Clinic. Dr. Psyrri reported honoraria from Merck Serono, Roche, MSD, AstraZeneca, Bristol-Myers Squibb, Bayer, Pfizer, Medscape, and Prime Oncology. Dr. Machiels reported a consulting or advisory role with Boehringer Ingelheim, Debiopharm Group, Innate Pharma, Merck, Nanobiotix, and Pfizer, and research funding from Bayer, Janssen Pharmaceuticals, Novartis, and Sanofi.

Read the article here.


Mehanna H et al. ESMO 2018, Abstract LBA9_PR.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44.

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Head & Neck Cancers

Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR

Head and neck cancer therapy toxicities greater in women, Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.

CYCORE reduces radiotherapy side effects in head and neck cancers, Peterson et al. ASCO 2018, Abstract 6063

Metastatic Lymph Nodes and Oral Cancer Survival , J Clin Oncol; ePub 2017 Sep 7; Ho, Kim, et al